In a bid to bolster its oncology franchise, Gilead Sciences has signed a multi-year collaboration with Tango Therapeutics to discover, develop and commercialise immuno-oncology therapies. With a total deal value of US$1.75 B, Tango received US$50 M upfront with the remainder in fees and potential milestone payments reflecting the early-stage nature of the deal. Gilead will have worldwide options to five targets of which Tango retains the option to co-develop and co-commercialise two. The agreement excluded Tango’s lead programmes.